1. Home
  2. IMRX
  3. IMRX News

Latest Immuneering Corporation (IMRX) News on October 8, 2025

IMRX

Argus Research

15 days ago

Daily – Vickers Top Insider Picks for 09/23/2025

IMRX

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 06/25/2025

We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
IMRX

Simply Wall St.

4 months ago

We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

IMRX

MT Newswires

4 months ago

Mizuho Raises Price Target on Immuneering to $10 From $8, Keeps Outperform Rating

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
IMRX

GlobeNewswire

4 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
IMRX

GlobeNewswire

4 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference
IMRX

GlobeNewswire

4 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

5 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
IMRX

GlobeNewswire

6 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award
IMRX

GlobeNewswire

7 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

7 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
IMRX

GlobeNewswire

7 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Slides As Insider Purchases Lose Another US$186k
IMRX

Simply Wall St.

7 months ago

Immuneering Slides As Insider Purchases Lose Another US$186k

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
IMRX

GlobeNewswire

8 months ago

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
IMRX

GlobeNewswire

8 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider
IMRX

Simply Wall St.

8 months ago

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
IMRX

GlobeNewswire

9 months ago

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Why Is Immuneering Stock Trading Higher On Tuesday?
IMRX

Benzinga

9 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

IMRX

MT Newswires

9 months ago

Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
IMRX

GlobeNewswire

9 months ago

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Aadi Bioscience Leads 3 Promising US Penny Stocks
IMRX

Simply Wall St.

10 months ago

Aadi Bioscience Leads 3 Promising US Penny Stocks

Immuneering Launches Pancreatic Cancer Advisory Board
IMRX

GlobeNewswire

10 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
IMRX

GlobeNewswire

10 months ago

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
IMRX

Benzinga

10 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

IMRX

MT Newswires

10 months ago

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
IMRX

GlobeNewswire

10 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
IMRX

GlobeNewswire

10 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor
IMRX

Simply Wall St.

a year ago

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

a year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX

Zacks

a year ago

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

IMRX

MT Newswires

a year ago

Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
IMRX

GlobeNewswire

a year ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
IMRX

Simply Wall St.

a year ago

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
IMRX

Zacks

a year ago

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

IMRX

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

Why Is Nanocap Immuneering Stock Trading Higher On Friday?
IMRX

Benzinga

a year ago

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

IMRX

MT Newswires

a year ago

Top Premarket Gainers

IMRX

MT Newswires

a year ago

Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating

IMRX

MT Newswires

a year ago

Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial

IMRX

MT Newswires

a year ago

Immuneering Shares Surge After 'Positive' Data in Phase 2a Pancreatic Cancer Trial

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
IMRX

GlobeNewswire

a year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
IMRX

GlobeNewswire

a year ago

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock
IMRX

Simply Wall St.

a year ago

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

IMRX

MT Newswires

a year ago

Chardan Adjusts Immuneering Price Target to $16 From $12, Maintains Buy Rating

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

a year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
IMRX

GlobeNewswire

a year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/18/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/17/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/14/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/13/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/12/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/11/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/10/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/07/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/06/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/05/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/04/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 06/03/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/31/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/30/2024

Immuneering to Present at the Jefferies Global Healthcare Conference
IMRX

GlobeNewswire

a year ago

Immuneering to Present at the Jefferies Global Healthcare Conference

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/29/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/28/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/24/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/23/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/22/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/21/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/20/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/17/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/16/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/15/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/14/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/13/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/10/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/09/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/08/2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

a year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully
IMRX

Simply Wall St.

a year ago

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/07/2024

Immuneering Recognizes Melanoma Awareness Month
IMRX

GlobeNewswire

a year ago

Immuneering Recognizes Melanoma Awareness Month

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/06/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/03/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/02/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/01/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/30/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/29/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/26/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/25/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/24/2024

IMRX

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/23/2024

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
IMRX

GlobeNewswire

a year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
IMRX

GlobeNewswire

2 years ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
IMRX

GlobeNewswire

2 years ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Director Acquires 7.5% More Stock
IMRX

Simply Wall St.

2 years ago

Immuneering Director Acquires 7.5% More Stock

Immuneering (IMRX) Plummets 71% in One Week: Here's Why
IMRX

Zacks

2 years ago

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
IMRX

GlobeNewswire

2 years ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
IMRX

GlobeNewswire

2 years ago

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
IMRX

GlobeNewswire

2 years ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
IMRX

GlobeNewswire

2 years ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference
IMRX

GlobeNewswire

2 years ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Share on Social Networks: